Holen Sie sich die Stockscreener-App
4.07
7.92%
-0.35
Handel nachbörslich:
4.03
-0.04
-0.98%
Schlusskurs vom Vortag:
$4.42
Offen:
$4.39
24-Stunden-Volumen:
415.22K
Relative Volume:
1.65
Marktkapitalisierung:
$273.09M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-71.17M
KGV:
-2.6258
EPS:
-1.55
Netto-Cashflow:
$-70.97M
1W Leistung:
-11.90%
1M Leistung:
-21.28%
6M Leistung:
-14.14%
1J Leistung:
+27.99%
1-Tages-Spanne:
$4.02
$4.455
1-Wochen-Bereich:
$4.02
$4.78
52-Wochen-Spanne:
$2.71
$7.795
Inozyme Pharma Inc Stock (INZY) Company Profile
Firmenname
Inozyme Pharma Inc
Sektor
Branche
Telefon
857-330-4340
Adresse
321 SUMMER STREET, BOSTON
Inozyme Pharma Inc Stock (INZY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-12 | Eingeleitet | Stifel | Buy |
| 2024-08-13 | Fortgesetzt | Jefferies | Buy |
| 2024-05-30 | Eingeleitet | Wells Fargo | Overweight |
| 2023-03-23 | Hochstufung | Jefferies | Hold → Buy |
| 2022-05-26 | Eingeleitet | Jefferies | Hold |
| 2022-02-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-29 | Eingeleitet | Needham | Buy |
| 2020-08-18 | Eingeleitet | BofA Securities | Buy |
| 2020-08-18 | Eingeleitet | Cowen | Outperform |
| 2020-08-18 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-18 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Inozyme Pharma Inc Aktie (INZY) Neueste Nachrichten
Piper Sandler raises Inozyme Pharma target to $43 from $40 - Investing.com
Piper Sandler raises Inozyme Pharma target to $43 from $40 By Investing.com - Investing.com UK
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights - The Manila Times
Inozyme Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Analysts Set Inozyme Pharma, Inc. (NASDAQ:INZY) Price Target at $16.14 - MarketBeat
Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Average Rating of “Buy” from Analysts - Defense World
Needham & Company LLC Reiterates Buy Rating for Inozyme Pharma (NASDAQ:INZY) - MarketBeat
Inozyme reports positive trial results for kidney disease therapy - Investing.com India
Inozyme reports positive trial results for kidney disease therapy By Investing.com - Investing.com Canada
Inozyme Pharma Bullish on Treatment for End-Stage Kidney Disease - MarketWatch
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701 - GlobeNewswire
The Manufacturers Life Insurance Company Grows Position in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
(INZY) Proactive Strategies - Stock Traders Daily
Inozyme Pharma presents kidney disease study at ASN Kidney Week By Investing.com - Investing.com Nigeria
Inozyme Pharma presents kidney disease study at ASN Kidney Week - Investing.com
Inozyme Pharma Announces Presentation of Interim Data from - GlobeNewswire
Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024 - Yahoo Finance
Short Interest in Inozyme Pharma, Inc. (NASDAQ:INZY) Decreases By 6.9% - MarketBeat
Dimensional Fund Advisors LP Purchases 205,417 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Inozyme Pharma, Inc. (NASDAQ:INZY) Shares Bought by Dimensional Fund Advisors LP - MarketBeat
Millennium Management LLC Acquires 1,084,341 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - MarketBeat
Cubist Systematic Strategies LLC Invests $84,000 in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Inozyme Pharma appoints new board member - Investing.com
Inozyme Pharma appoints new board member By Investing.com - Investing.com South Africa
Inozyme Pharma Welcomes New Director Erik Harris - TipRanks
Inozyme appoints Erik Harris to board of directors - TipRanks
Inozyme Pharma Appoints Erik Harris to its Board of Directors - citybiz
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its - The Bakersfield Californian
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors - GlobeNewswire
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of - EIN News
How the (INZY) price action is used to our Advantage - Stock Traders Daily
Inozyme Pharma, Inc. (NASDAQ:INZY) Shares Purchased by American Century Companies Inc. - Defense World
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Wedbush Reiterates "Outperform" Rating for Inozyme Pharma (NASDAQ:INZY) - MarketBeat
Deerfield Management Company L.P. Series C Takes Position in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Blue Owl Capital Holdings LP Cuts Holdings in Inozyme Pharma, Inc. (NASDAQ:INZY) - MarketBeat
Long Term Trading Analysis for (INZY) - Stock Traders Daily
Inozyme Pharma Presents New Data at the American Society - GlobeNewswire
Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) - The Bakersfield Californian
Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting - StockTitan
Affinity Asset Advisors LLC Acquires 213,733 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Inozyme Pharma, Inc. (NASDAQ:INZY) Stock Position Raised by Affinity Asset Advisors LLC - MarketBeat
Inozyme Pharma, Inc. (NASDAQ:INZY) Holdings Raised by Samlyn Capital LLC - Defense World
Samlyn Capital LLC Has $14.94 Million Stock Position in Inozyme Pharma, Inc. (NASDAQ:INZY) - MarketBeat
Bank of New York Mellon Corp Grows Position in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
How to Take Advantage of moves in (INZY) - Stock Traders Daily
Stifel Nicolaus Initiates Coverage on Inozyme Pharma (NASDAQ:INZY) - Defense World
Why Analyst Says Rare Disease-Focused Inozyme Pharma Stock 'Could Be Worth A Look' - Benzinga
Inozyme Pharma (NASDAQ:INZY) Coverage Initiated at Stifel Nicolaus - MarketBeat
Inozyme stock draws buy at Stifel on lead drug (NASDAQ:INZY) - Seeking Alpha
Finanzdaten der Inozyme Pharma Inc-Aktie (INZY)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):